Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106457 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ARIPK1POLB | |
| SCHEMBL6106460 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ARIPK1POLB | |
| SCHEMBL6108396 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ARIPK1POLB | |
| SCHEMBL6108399 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ARIPK1POLB | |
| SCHEMBL6108395 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2NPC1RAB9ARIPK1POLB | |
| SCHEMBL6106325 | 0.89 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL6106331 | 0.89 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL6108649 | 0.86 | CREBBP (0.33) | SMN1; SMN2NPC1RAB9ACREBBP | |
| SCHEMBL6108641 | 0.86 | CREBBP (0.33) | SMN1; SMN2NPC1RAB9ACREBBP | |
| SCHEMBL6106612 | 0.84 | RIPK1 (0.37) | SMN1; SMN2NPC1RAB9ARIPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1539733-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | SMN1; SMN2 215/4885NPC1 654/4885RAB9A 2352/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | SMN1; SMN2 215/4885NPC1 654/4885RAB9A 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.